CAR T cells for treating autoimmune diseases

Area of Science:

• Immunology
• Cell Therapy
• Autoimmune Diseases

Background:

• Autoimmune disorders involve immune cells attacking the body's tissues.
• Current treatments like immunosuppressants are often not curative.
• There's a need for advanced, potentially curative therapies for severe autoimmune diseases.

Purpose of the Study:

• To review the developments of CAR T-cell therapy for autoimmune disorders.
• To cover clinical results and preclinical advancements in CAR T-cell applications.
• To discuss safety, manufacturing, and future availability of CAR T-cell products.

Main Methods:

• Review of clinical results using anti-CD19 and anti-BCMA CAR T-cells for B cell elimination.
• Exploration of preclinical models with chimeric autoantibody receptor (CAAR) T-cells and regulatory CAR T-cells.
• Discussion of safety, manufacturing, mRNA technologies, and automation for CAR T-cells.

Main Results:

• Early clinical results show efficacy of CAR T-cells in eliminating B cells for conditions like lupus and myasthenia gravis.
• Preclinical models demonstrate the potential of CAAR T-cells to target specific autoantibody-producing B cells.
• Development of regulatory CAR T-cells aims to dampen, not eliminate, autoreactive immune cells.

Conclusions:

• CAR T-cell therapy is emerging as a promising, potentially curative treatment for autoimmune diseases.
• Targeted cell therapies offer new avenues beyond broad immunosuppression.
• Advancements in technology and manufacturing are crucial for future accessibility of CAR T-cell therapies.